MedTrace Logo

Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer

NCT06609759 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 197

Last updated 2026-05-05

No results posted yet for this study

Summary

For patients with stage II-III gastric cancer after radical D2 resection and R0 resection, postoperative adjuvant therapy guided by ctDNA-MRD (MRD-GATE external cohort) was not inferior to the standard chemotherapy regimen (this cohort).

Conditions

  • Stage II-III Gastric Cancer

Interventions

DRUG

Standard chemotherapy regimen

In terms of postoperative adjuvant treatment, treatment is based on the guideline standard treatment plan, which can be adjusted according to the doctor's experience.

Sponsors & Collaborators

  • Shandong Provincial Hospital

    collaborator OTHER_GOV

  • Jinan Central Hospital

    collaborator OTHER

  • Yantai Yuhuangding Hospital

    collaborator OTHER

  • The Affiliated Hospital of Qingdao University

    collaborator OTHER

  • Qilu Hospital of Shandong University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2028-01-01
Completion
2029-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06609759 on ClinicalTrials.gov